Biopharma holds back PE
PerkinElmer sees the benefit of a cost-cutting effort in its third-quarter results as net income rises 45 per cent, but biopharma puts in a lacklustre performance.
Archives for October 22, 2003
GMP on the agenda
Mixed news on GMP compliance, as Australia's API has its manufacturing license renewed after a six-week suspension and GSK unveils a US FDA probe.
Biovitrum bolsters contract business
Biotechnology company Biovitrum has established a new business unit, Biovitrum Biopharmaceuticals, to strengthen its position as a supplier of process development and contract manufacture of recombinant proteins. The move follows a three-year...
Genome delays hit Applied Bio
Budgetary delays at genomic centres, as well as mass spectrometry manufacturing obstacles, have held back Applied Bio's first quarter figures.
Bar code buy for McKesson
McKesson buys Sky Packaging in a deal that primes it to capitalise on the implementation of US plans to require bar-coding of all unit-dose drugs.
Off-the-peg LIMS
Sales of commercial Laboratory Information Management Systems (LIMS) are set for strong growth as manufacturers turn away from home-grown systems
EU IPO rush to follow US?
October has seen a rush by US biotechnology companies to list on the stock markets, bringing to an end an Initial Public Offering (IPO) drought lasting more than 18 months. Is Europe destined to follow?
New bioreactor from Integra
Switzerland's Integra Biosciences extends its CELLine range of disposable bioreactor vessels with a new version intended for use with adherent cell lines.
New paradigm for hormonal disease?
A UK company has discovered a receptor that could serve as a new drug target for fertility control, abnormal puberty and hormone-dependent cancers.